Skip to main content
SpringerLink
Log in

Efficacy and safety of trifluridine/tipiracil (TAS-102) in patients with metastatic colorectal cancer: a systematic review and meta-analysis

  • RESEARCH ARTICLE
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

A Correction to this article was published on 03 August 2023

This article has been updated

Abstract

Objectives

The purpose of this meta-analysis is to evaluate the efficacy and safety of TAS-102 in treating metastatic colorectal cancer (mCRC) using the most recent data available.

Methods

The literature on the efficacy and safety of TAS-102 versus placebo and/or best supportive care (BSC) in mCRC was obtained through a systematic search of PubMed, Embase, and Web of Science databases through January 2023. Identify the included literature and extract pertinent data, such as the overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF), disease control rate (DCR), incidence of adverse events (AEs) and serious adverse events (SAEs).

Results

There were eight eligible articles that included 2903 patients (1964 TAS-102 versus 939 Placebo and/or BSC). In this meta-analysis, TAS-102 treatment resulted in longer OS, PFS, TTF, and higher DCR in patients with mCRC versus placebo and/or BSC. TAS-102 improved OS and PFS in subgroup analyses of mCRC patients with KRAS wild-type and KRAS mutant-type. In addition, TAS-102 did not increase the incidence of serious adverse events.

Conclusion

TAS-102 can enhance the prognosis of mCRC patients whose standard therapy has failed, regardless of KRAS mutation status, and its safety is acceptable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig.5
Fig.6

Similar content being viewed by others

Data availability

All data used in this study were provided by the corresponding author upon reasonable request.

Change history

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.

    Article  PubMed  Google Scholar 

  2. Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022;72:372–401. https://doi.org/10.3322/caac.21728.

    Article  PubMed  Google Scholar 

  3. Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10–32. https://doi.org/10.3322/caac.21728.

    Article  CAS  PubMed  Google Scholar 

  4. Boukouris AE, Theochari M, Stefanou D, Felekouras E, Gogas H, Ziogas DC. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: a 2022 update. Crit Rev Oncol Hematol. 2022;173:103663. https://doi.org/10.1016/j.critrevonc.2022.103663.

    Article  PubMed  Google Scholar 

  5. Singh P, Waghambare P, Khan TA, Omri A. Colorectal cancer management: strategies in drug delivery. Expert Opin Drug Deliv. 2022;19:653–70. https://doi.org/10.1080/17425247.2022.2084531.

    Article  CAS  PubMed  Google Scholar 

  6. Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, et al. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci. 2021;17(14):3837–49. https://doi.org/10.7150/ijbs.64077.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2021;13:993–1001. https://doi.org/10.1016/S1470-2045(12)70345-5.

    Article  CAS  Google Scholar 

  8. Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909–19. https://doi.org/10.1056/NEJMoa1414325.

    Article  PubMed  Google Scholar 

  9. Van Cutsem E, Mayer RJ, Laurent S, Winkler R, Grávalos C, Benavides M, et al. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer. 2019;90:63–72. https://doi.org/10.1016/j.ejca.2017.10.009.

    Article  CAS  Google Scholar 

  10. Xu J, Kim TW, Shen L, Sriuranpong V, Pan H, Xu R, et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol. 2018;36(4):350–8. https://doi.org/10.1200/JCO.2017.74.3245.

    Article  CAS  PubMed  Google Scholar 

  11. Weiss L, Karthaus M, Riera-Knorrenschild J, Kretzschmar A, Welslau M, Vehling-Kaiser U, et al. TALLISUR study group. Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial. ESMO Open. 2022;7(1):100391. https://doi.org/10.1016/j.esmoop.2022.100391.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Emura T, Suzuki N, Yamaguchi M, Ohshimo H, Fukushima M. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol. 2004;25(3):571–8.

    CAS  PubMed  Google Scholar 

  13. van der Velden DL, Opdam FL, Voest EE. TAS-102 for treatment of advanced colorectal cancers that are no longer responding to other therapies. Clin Cancer Res. 2016;22(12):2835–9. https://doi.org/10.1158/1078-0432.CCR-15-2783.

    Article  CAS  PubMed  Google Scholar 

  14. Chen D, Wu YS, Lin H, Wang Y, Li L, Zhang T. Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis. Cancer Manag Res. 2018;10:2915–24. https://doi.org/10.2147/CMAR.S174584.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Yoshino T, Cleary JM, Van Cutsem E, Mayer RJ, Ohtsu A, Shinozaki E, et al. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. Ann Oncol. 2020;31(1):88–95. https://doi.org/10.1016/j.annonc.2019.10.005.

    Article  CAS  PubMed  Google Scholar 

  16. Pietrantonio F, Fucà G, Manca P, Pagani F, Raimondi A, Prisciandaro M, et al. Validation of the colon life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial. Tumori. 2021;107(4):353–9. https://doi.org/10.1177/0300891620960808.

    Article  CAS  PubMed  Google Scholar 

  17. Cheung WY, Kavan P, Dolley A. Quality of life in a real-world study of patients with metastatic colorectal cancer treated with trifluridine/tipiracil. Curr Oncol. 2020;27(5):e451–8. https://doi.org/10.3747/co.27.6533. (Epub 2020 Oct 1).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89. https://doi.org/10.1186/s13643-021-01626-4.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. https://doi.org/10.1186/1471-2288-14-135.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785–805. https://doi.org/10.1177/0962280216669183.

    Article  PubMed  Google Scholar 

  21. Wells G, Shea B, O’Connell D, Robertson J, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomised Studies in Meta-Analyses. Symposium on Systematic Reviews: Beyond the Basics. 2014.

  22. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.

    Article  PubMed  Google Scholar 

  23. de Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam symptom checklist. Br J Cancer. 1990;62:1034–8.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Colwell HH, Mathias SD, Turner MP, Lu J, Wright N, Peeters M, et al. Psychometric evaluation of the FACT colorectal cancer symptom index (FCSI-9): reliability, validity, responsiveness, and clinical meaningfulness. Oncologist. 2010;15:308–16. https://doi.org/10.1634/theoncologist.2009-0034.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Leowattana W, Leowattana P, Leowattana T. Systemic treatment for metastatic colorectal cancer. World J Gastroenterol. 2023;29:1569–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Shin AE, Giancotti FG, Rustgi AK. Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharmacol Sci. 2023;44:222–36. https://doi.org/10.1016/j.tips.2023.01.003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5:22. https://doi.org/10.1038/s41392-020-0116-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35. https://doi.org/10.1056/NEJMoa1504627.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26. https://doi.org/10.1056/NEJMoa1104621.

    Article  CAS  PubMed  Google Scholar 

  30. Weng J, Li S, Zhu Z, Liu Q, Zhang R, Yang Y, et al. Exploring immunotherapy in colorectal cancer. J Hematol Oncol. 2022;15:95. https://doi.org/10.1186/s13045-022-01294-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–12. https://doi.org/10.1016/S0140-6736(12)61900-X.

    Article  CAS  PubMed  Google Scholar 

  32. Bachet JB, Wyrwicz L, Price T, Cremolini C, Phelip JM, Portales F, et al. Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. ESMO Open. 2020;5:e000698. https://doi.org/10.1136/esmoopen-2020-000698.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This study is supported by the National Natural Science Foundation of China (No. 81860104) and Natural Science Foundation of Guangxi Zhuang autonomous Region (No. 2017GXNSFAA198299).

Author information

Authors and Affiliations

  1. Department of Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

    Fengxiang Huang, Haiyan Yang, Wenguang Bao, Yehong Bin, Shengsheng Zhou & Man Wang

  2. Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

    Xiaoping Lv

Authors
  1. Fengxiang Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haiyan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wenguang Bao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yehong Bin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shengsheng Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Man Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiaoping Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XL was responsible for the conception and design of the study. FH contributed to the literature research, analysis and interpretation of data for the work, and drafting and revision of the manuscript. HY, WB, YB, SZ and MW contributed to the collection and assembly of data. All gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy.

Corresponding author

Correspondence to Xiaoping Lv.

Ethics declarations

Conflict of interest

There was no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised due to a retrospective Open Access cancellation.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 843 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, F., Yang, H., Bao, W. et al. Efficacy and safety of trifluridine/tipiracil (TAS-102) in patients with metastatic colorectal cancer: a systematic review and meta-analysis. Clin Transl Oncol 26, 468–476 (2024). https://doi.org/10.1007/s12094-023-03268-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-023-03268-5

Keywords

Search

Navigation